Fig 2.

Cumulative incidence of breast cancer–specific death according to CHEK2*1100delC carrier status for all participants, separated by estrogen receptor status: (A) all patients; (B) estrogen receptor–positive patients; (C) estrogen receptor–negative patients. Patients were included at time of blood sampling following a first breast cancer and were observed until death or end of follow-up, whichever came first. Other causes of death were considered as a competing event. Multifactorially adjusted hazard ratio (HR) for breast cancer–specific death in heterozygotes versus noncarriers stratified by study and adjusted for age at diagnosis, year of diagnosis, body mass index, menopausal status, tumor size, lymph node status, progesterone receptor status, and human epidermal growth factor receptor 2.